Non-invasive detection of crizotinib resistance in ALK-rearranged lung adenocarcinoma directs treatment with next-generation ALK inhibitors
Latest Information Update: 29 Jul 2016
At a glance
- Drugs Crizotinib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- 29 Jul 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology